Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Cited by 220 Publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Immunol, 2018, 19(6):561-570

PubMed: 29777213 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Nat Genet, 2014, 46(2):166-70

PubMed: 24413734 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31704808 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Nat Neurosci, 2019, 22(5):719-728

PubMed: 30936558 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 101164/rccm201902-0451OC

PubMed: 31738079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

J Extracell Vesicles, 2019, 9(1):1698889

PubMed: 31853340 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2309

PubMed: 31857430 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5038-5048

PubMed: 31182436 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )
Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Oncogene, 2019, 38(12):2135-2150

PubMed: 30459358 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0449

PubMed: 31744897 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4819

PubMed: 30894630 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17171

PubMed: 31748572 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(12)

PubMed: 31888247 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )
PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212860

PubMed: 30794695 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Sci Transl Med, 2018, 10(427)

PubMed: 29437150 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(21):2837-2849

PubMed: 29511345 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30036966 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5362

PubMed: 29599515 ( click the link to review the publication )
Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(3):286-298

PubMed: 28678601 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(374)

PubMed: 28123069 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Hepatology, 2017, 66(6):1934-1951

PubMed: 28714104 ( click the link to review the publication )

Mol Cell, 2017, 66(5):635-647

PubMed: 28575659 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3029

PubMed: 29048432 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14381-14390

PubMed: 28684419 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(8):1903-1913

PubMed: 27931141 ( click the link to review the publication )

J Neurophysiol, 2017, 118(1):595-609

PubMed: 28446585 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73871-73883

PubMed: 29088753 ( click the link to review the publication )

Nat Commun, 2016, 7:10060

PubMed: 26725982 ( click the link to review the publication )

Nat Commun, 2016, 7:11889

PubMed: 27297662 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(51):E8228-E8237

PubMed: 27930322 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )
Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

Development, 2016, 143(10):1674-87

PubMed: 26989177 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

J Gen Virol, 2016, 97(5):1134-1144

PubMed: 26879209 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )
Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 80:56-65

PubMed: 26296860 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Oncotarget, 2015, 6(4):1967-80

PubMed: 25596742 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(36):38854-65

PubMed: 26513174 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )
J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

PLoS Biol, 2013, 11(3):e1001515

PubMed: 23526884 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )
J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2978-91

PubMed: 23974111 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )
Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	NE[1eppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{D4RlczKGh?	M1nSbWROW09?	MXTJR\|UxRTBwMECwNFch\|ryP	NYWxNW97OTd7NU[wPFA>
K562	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoXaO\|IhcA>?	NF62bm9FVVOR	NFL3U\|lKSzVyPUCuNFAyKM7:TR?=	M3fISVE4QTV4MEiw
M07e	M33PeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUS3NkBp	NWTvVYlTTE2VTx?=	NYHxcpVrUUN3ME2wMlAxOTJizszN	MmHzNVc6PTZyOEC=
ALL3	M1jO[GN6fG:2b4jpZ{BCe3OjeR?=	NELnV4MxNjIQvF2=	NV;RPHM4PzJiaB?=	MofNSG1UVw>?	NWnUb2pNUUN3ME2wMlAxODRizszN	MljVNVk5QDl3NEC=
CML	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoLsNlAhdWmw	M2nGcGROW09?	NXPJfmZLUUN3ME2wMlAxOSEQvF2=	MnmyNVkzOTlyMU[=
BA/F3	Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4DFfFczKGh?	MV7EUXNQ	NFn5UJlKSzVyPU[uOVg6KM7:TR?=	M{HXRVI{ODh6NkS0
BA/F3	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlPrO\|IhcA>?	MVXEUXNQ	M2nCU2lv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh\|zszN	MUOyN\|A5QDZ2NB?=
BA/F3	NIruXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYrs[lRRPzJiaB?=	MUDEUXNQ	MlziTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>?	M3v4VFI{ODh6NkS0
BA/F3	NEjTSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4DUXFczKGh?	NWjQSY5LTE2VTx?=	MXvJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1?	NVXJfWZGOjNyOEi2OFQ>
BA/F3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV:3NkBp	NXzkdpZITE2VTx?=	M2\6SGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6\|ryP	M{XhXlI{OzBzN{Cz
BA/F3	NGnZO\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVe3NkBp	NXTRU4l{TE2VTx?=	MnXBTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN\|LPxE1?	NITBVI0zOzNyMUewNy=>
BA/F3	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYm3NkBp	M4fPe2ROW09?	NULRU3g4UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiR{K1NGUhdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxPTIQvF2=	M1yyb\|I{OzBzN{Cz
BA/F3	MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFi4T5M4OiCq	M1TqSWROW09?	MUXJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO	M1O4VVI{OzBzN{Cz
BA/F3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH;DOYM4OiCq	NXTVV5M3TE2VTx?=	MV;JcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>?	NFjDNHQzOzNyMUewNy=>
BA/F3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH3sXI84OiCq	MmL4SG1UVw>?	MV3JcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO\|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=>	MlHVNlM{ODF5MEO=
BA/F3	MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn[2O\|IhcA>?	M3r1e2ROW09?	NGHDW5pKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFAzO87:TR?=	NHfselgzOzNyMUewNy=>
BA/F3	MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIDPTHA4OiCq	MoTaSG1UVw>?	MVzJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=>	MX:yN\|MxOTdyMx?=
BA/F3	NUDUUZFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVK3NkBp	MmLsSG1UVw>?	MW\JcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCyMlXPxE1?	MmfBNlM{ODF5MEO=
T cell	Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYK3NkBp	NV74NIxbTE2VTx?=	Ml7rTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0>	NVXDOnNTOTdzNUS1NVI>
WiDr	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUnHSmFCPzJiaB?=	M2TsXGROW09?	M3zHcGlEPTB;MD6wOVIh\|ryP	NWjRTIVEOTV4MUW1NVI>
PC3	NXvnOI1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml3hO\|IhcA>?	M2jxSWROW09?	M1XqTWlEPTB;MD6wNFk1KM7:TR?=	NVr3V3V4OTV4MUW1NVI>
MDA-MB-231	M13oUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlLvO\|IhcA>?	MmHxSG1UVw>?	MW\JR\|UxRTBwMEGyJO69VQ>?	NF\lW5MyPTZzNUWxNi=>
Hs578T	MYjDfZRwfG:6aXOgRZN{[Xl?		MWK3NkBp	NUnwOmZpTE2VTx?=	NHLKeIZIUTVyPUCuNFMh\|ryP	NFW4[YEzPDBzNUOyOy=>
HMEC	NXnSdYxXS3m2b4TvfIlkKEG\|c3H5		Mmf2O\|IhcA>?	MXTEUXNQ	Mn7LS2k2OD1zLkig{txO	NWrvSZU5OjRyMUWzNlc>
DU145	MljRR5l1d3SxeHnjJGF{e2G7		MUC3NkBp	NFq3W25FVVOR	MV3HTVUxRTBwMU[g{txO	NYHGOWRzOjRyMUWzNlc>
U251	NGP6[Y5EgXSxdH;4bYMhSXO\|YYm=		MXy3NkBp	M1TpbmROW09?	NWnzVVVyT0l3ME2yMlgyKM7:TR?=	MkfiNlQxOTV\|Mke=
NCI60	MYnDfZRwfG:6aXOgRZN{[Xl?		NH7CUVc4OiCq	NInoNHZFVVOR	MlnXS2k2OD13Lkeg{txO	M2nMNFI1ODF3M{K3
MALME-3M	M4rSdGN6fG:2b4jpZ{BCe3OjeR?=		MmXDO\|IhcA>?	MXrEUXNQ	NGDyRVVIUTVyPU[uOlEh\|ryP	NFHyWWEzPDBzNUOyOy=>
KM12	Mo\OR5l1d3SxeHnjJGF{e2G7		NHPiZpo4OiCq	NWPxVVNITE2VTx?=	NXfueVF6T0l3ME23MlQ1KM7:TR?=	NEi4NlczPDBzNUOyOy=>
SW620	NYP0T4pRS3m2b4TvfIlkKEG\|c3H5		MX63NkBp	M{naVmROW09?	MkTOS2k2OD16LkSzJO69VQ>?	M{PH[\|I1ODF3M{K3
RXF 393NL	M2rXXWN6fG:2b4jpZ{BCe3OjeR?=		MmPJOEBl[Xm\|	MnvMSG1UVw>?	MVrJR\|UxRTBwMEKxO{DPxE1?	NHrvNVQzOzJ3M{C3OC=>
LXFA 983L	NYqxOmZpS3m2b4TvfIlkKEG\|c3H5		NGWydFg1KGSjeYO=	MXXEUXNQ	MnfvTWM2OD1yLkC1OlUh\|ryP	NWHOT\|J4OjN{NUOwO\|Q>
PRXF DU145	M1;3[2N6fG:2b4jpZ{BCe3OjeR?=		NW\5OWFYPCCmYYnz	Mk\nSG1UVw>?	NVz5PJA5UUN3ME2wMlA3OjNizszN	NHjjWXEzOzJ3M{C3OC=>
PAXF 1657L	MnjVR5l1d3SxeHnjJGF{e2G7		M3XnU\|Qh\GG7cx?=	MoXJSG1UVw>?	MlTZTWM2OD1yLkGyNUDPxE1?	NFj2dowzOzJ3M{C3OC=>
CXF 1103L	M3vtWmN6fG:2b4jpZ{BCe3OjeR?=		MWC0JIRigXN?	NYTKeXdWTE2VTx?=	NHfFPGJKSzVyPUSuN\|Yh\|ryP	MWCyN\|I2OzB5NB?=
GXF251L	MnK5R5l1d3SxeHnjJGF{e2G7		MUi0JIRigXN?	Mlr4SG1UVw>?	MWnJR\|UxRTJwMkWg{txO	NGPvR\|czOzJ3M{C3OC=>
NCI-H23	NIHTb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{T3OVczKGh?	MmLYSG1UVw>?	MljNTWM2OD1{LkK3JO69VQ>?	MoLSNlM2OjFyMkC=
HCT116	NH7aXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MU[3NkBp	NX;jTFlVTE2VTx?=	NISyOpZKSzVyPUKuN{DPxE1?	NWD5U2NDOjN3MkGwNlA>
MCF7	MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml\zO\|IhcA>?	NWrSUpNNTE2VTx?=	NWG5NFhTUUN3ME2yMlU4KM7:TR?=	NEfIVmUzOzV{MUCyNC=>
NCI-H460	M3ryb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnLzO\|IhcA>?	NFy0e4hFVVOR	NHTRcHVKSzVyPUiuPVkh\|ryP	MXuyN\|UzOTB{MB?=
DLD1	NHPxUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYPFc4ZWPzJiaB?=	NXLnN2FpTE2VTx?=	MoPWTWM2OD12Lk[g{txO	NHvpUIIzOzV4N{m2NC=>
NCI-H661	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NETWT2E4OiCq	NYHNWXBCTE2VTx?=	MWXJR\|UxRTdwODFOwG0>	M{fEdFI{PTZ5OU[w
A549	M2Lmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXO3NkBp	MXrEUXNQ	M33tUWlEPTB;OD6yJO69VQ>?	NHjSR5YzOzV4N{m2NC=>
U937	NXu2[5hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVG3NkBp	NH7oVFhFVVOR	NHrHNHFKSzVyPUGyMlIh\|ryP	NIPE[mUzOzV4N{m2NC=>
HEK293	NF\iXIdHfW6ldHnvckBCe3OjeR?=	NY\mTGdqOTEEoN88US=>		NHvMPVJFVVOR	NH:ycXVKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm\|LYTh[4dm\CCPeYSxJItqdmG\|ZTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IIfpeIghUUN3MDDv[kAxNjB4M988US=>	NYXnPGh6OjJ5N{C2NVA>
HUVEC	M3;KcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTG[2k{OC5zNdMg{txO	M163eFczKGh?	NF\6VJlFVVOR	M2n5fWlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC\|bX;veIghdXW\|Y3zlJINmdGy\|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=>	MkPSNlI5PTN7OUO=
HUVEC	MmDNSpVv[3Srb36gRZN{[Xl?	Mn7INVXDqM7:TR?=	NXXIOnFDPzJiaB?=	M4LjTmROW09?	NWXKeVh{UW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1?	M{XI[\|IzQDV\|OUmz
Plasmodium falciparum	Mn3PSpVv[3Srb36gRZN{[Xl?	MV2xNOKh\|ryP	MljNNVUhdWmw	NV7HWXVMTE2VTx?=	MV;Jcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0>	MoPmNlQ2PTB\|M{C=
PC3	M3;mVGZ2dmO2aX;uJGF{e2G7	MXuwMlEh\|ryP	NHLmdnE2KGh?	NX7tZnVwTE2VTx?=	MoTYTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P	NGXJTpgyQTR4Mkm3OS=>
DU145	MYXGeY5kfGmxbjDBd5NigQ>?	NEWxencxNjFizszN	NEnzXJQ2KGh?	NGDOWHJFVVOR	M3nONmlvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7N	NGDXZ4cyQTR4Mkm3OS=>
PC3	MnTBT4lv[XOnIFHzd4F6	MV:wMlEh\|ryP	NX\wV45sPSCq	Mnm5SG1UVw>?	MkP3TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?=	Mni5NVk1PjJ7N{W=
DU145	MX3LbY5ie2ViQYPzZZk>	NIHERogxNjFizszN	MXW1JIg>	M4PGVGROW09?	NHPLN4RKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0>	M2DnelE6PDZ{OUe1
PC3	M1uxO2tqdmG\|ZTDBd5NigQ>?	MVGwMlEh\|ryP	MX:1JIg>	Mlu1SG1UVw>?	MUDJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0>	NUnjXXJtOTl2NkK5O\|U>
DU145	MYDLbY5ie2ViQYPzZZk>	NXiyTItVOC5zIN88US=>	NFPUTGE2KGh?	NE\0fHFFVVOR	M1[zOGlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P	NID3T\|IyQTR4Mkm3OS=>
Huh7	NVjvT4NSSW62aY\pdoFtKEG\|c3H5	NIC3XnEzNjVizszN	NEXyZ3g1KGSjeYO=	M1fBd2ROW09?	M1viR2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?=	MVWxO\|M3ODZ5Nh?=
C6/36	MVfBcpRqfmm{YXygRZN{[Xl?	Mlr3Nk42KM7:TR?=	NXLLdnBZPCCmYYnz	M2XXXWROW09?	M{XXbmlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN\|Yh[2WubIOgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1?	M1K1Z\|E4OzZyNke2
U937	NG\wTlBHfW6ldHnvckBCe3OjeR?=	MXqxJO69VQ>?	NI[3N5IyKGh?	MnPUSG1UVw>?	NFSxdphT\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?=	NE\2VWEyPzZ6NEC5PS=>
U937	MUnGeY5kfGmxbjDBd5NigQ>?	NH34W2UyKM7:TR?=	NXLme5FDOSCq	NI\ERmpFVVOR	M3jQdXJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{	NGHXRYUyPzZ6NEC5PS=>
murine mast cell	M1fpRmZ2dmO2aX;uJGF{e2G7	MkjNNUDPxE1?	Ml;xNlQhcA>?	M2PRXGROW09?	M1v3UGlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP	NW\xTGY6OTd4OESwPVk>
BV-173	M{nlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHjSYlKSzVyPUCuNFAxODByMUC5JO69VQ>?	Mmm1V2FPT0WU
K-562	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTBwMECwNFAxOjZ4IN88US=>	MWrTRW5ITVJ?
BL-70	MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlKwTWM2OD1yLkCwNFAxODh{MjFOwG0>	NFm0fFZUSU6JRWK=
EM-2	NIrpW\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHrToU2UUN3ME2wMlAxODByMUC4JO69VQ>?	MYnTRW5ITVJ?
LAMA-84	NHK0e2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1i0eGlEPTB;MD6wNFAxODN{MTFOwG0>	MmW5V2FPT0WU
MEG-01	MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIO0WWpKSzVyPUCuNFAxODB7ODFOwG0>	NVjXNYV6W0GQR1XS
EoL-1-cell	MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17mNWlEPTB;MD6wNFAxOTNzIN88US=>	M1nE[XNCVkeHUh?=
CTV-1	MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2n5UGlEPTB;MD6wNFAxPDB2IN88US=>	M2LDO3NCVkeHUh?=
TE-15	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTDTWM2OD1yLkCwOVg6KM7:TR?=	Moi4V2FPT0WU
NOS-1	MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnTTWM2OD1yLkCwOlE{KM7:TR?=	M4fkWXNCVkeHUh?=
D-336MG	Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXleoZiUUN3ME2wMlAxPjNizszN	MVjTRW5ITVJ?
LB1047-RCC	NXXESWwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHjUI1RUUN3ME2wMlAxQTh7IN88US=>	MkXmV2FPT0WU
LB996-RCC	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIWzSnZKSzVyPUCuNFA6QTFizszN	M2fJWHNCVkeHUh?=
SW982	NVTC[HF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTkVYN[UUN3ME2wMlAyOTF3IN88US=>	NYr0d\|A2W0GQR1XS
TK10	NUP4V45GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2L0OmlEPTB;MD6wNVE4PCEQvF2=	M1POOHNCVkeHUh?=
A704	NFThT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TMOWlEPTB;MD6wNVQ6OSEQvF2=	M3fROXNCVkeHUh?=
TE-8	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;VTWM2OD1yLkCxOVc3KM7:TR?=	M3LuNXNCVkeHUh?=
DOHH-2	NETl[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3O5T2lEPTB;MD6wNVcyQSEQvF2=	MnzlV2FPT0WU
HOP-62	NGSwRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTBwMEG4N\|Qh\|ryP	NVn0VIdjW0GQR1XS
TE-12	MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnzVI1KSzVyPUCuNFE5PjFizszN	MYLTRW5ITVJ?
KGN	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTBwMEG5OFIh\|ryP	M3rkbnNCVkeHUh?=
NCI-H1648	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PkTWlEPTB;MD6wNlAyOSEQvF2=	NYjCRlJqW0GQR1XS
OS-RC-2	NETaZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYn3XHB6UUN3ME2wMlAzODNizszN	NWDUOYRnW0GQR1XS
GB-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTCe5IzUUN3ME2wMlAzOTV5IN88US=>	M{DFfXNCVkeHUh?=
RXF393	NHnPb\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17PSmlEPTB;MD6wNlM2PyEQvF2=	MofiV2FPT0WU
LC-2-ad	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTBwMEK1PFYh\|ryP	MWfTRW5ITVJ?
KS-1	NF7sbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHRbHpKSzVyPUCuNFI4OyEQvF2=	NXXtSYFJW0GQR1XS
ETK-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTBwMEK4N\|Ih\|ryP	NFnDVWVUSU6JRWK=
SW954	NXHyO4xlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVy2RmNiUUN3ME2wMlAzQTJ5IN88US=>	NX7UNYg2W0GQR1XS
Becker	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrQTppKSzVyPUCuNFMxODNizszN	M16yW3NCVkeHUh?=
MZ1-PC	NHjQZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DuUmlEPTB;MD6wN\|EyQSEQvF2=	NYqxdYR3W0GQR1XS
ES6	Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLIXpJjUUN3ME2wMlA{OTl\|IN88US=>	MnL1V2FPT0WU
KURAMOCHI	NHWwW\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XOdmlEPTB;MD6wN\|Q5PyEQvF2=	M2PCZ3NCVkeHUh?=
CGTH-W-1	NWnSTGNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fSdGlEPTB;MD6wN\|U1QCEQvF2=	M2PofnNCVkeHUh?=
VA-ES-BJ	NX[zNGh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfHb5lkUUN3ME2wMlA{QTB{IN88US=>	MYjTRW5ITVJ?
LXF-289	M1nmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTBwMEO5OVYh\|ryP	NHW4XWNUSU6JRWK=
MPP-89	M{f1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUOyTpUxUUN3ME2wMlA1ODR7IN88US=>	NGewW4NUSU6JRWK=
SW872	MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\zTlNKSzVyPUCuNFQyPjFizszN	NWDxT\|BNW0GQR1XS
SNB75	M3LsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTkTWM2OD1yLkC0OFM2KM7:TR?=	NUfVbY83W0GQR1XS
PSN1	M1jscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37GeGlEPTB;MD6wOFQ4PCEQvF2=	MWnTRW5ITVJ?
LB831-BLC	NHLXZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjmTWM2OD1yLkC0OlA6KM7:TR?=	MYHTRW5ITVJ?
MFH-ino	NVTHXmk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTBwMES3NlQh\|ryP	NI\KVZFUSU6JRWK=
TGBC24TKB	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTBwMES3OlEh\|ryP	NHu1NWxUSU6JRWK=
A388	NWDtNog2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETTTo9KSzVyPUCuNFUxQTVizszN	MlLoV2FPT0WU
BB30-HNC	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDOTWM2OD1yLkC1OFM4KM7:TR?=	NYDjRnpRW0GQR1XS
GI-ME-N	NYnhSGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4faZ2lEPTB;MD6wOlEyQCEQvF2=	MlnOV2FPT0WU
TGBC1TKB	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUf2NYd4UUN3ME2wMlA3OTZ2IN88US=>	MlrXV2FPT0WU
TE-10	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LGTWlEPTB;MD6wOlM2PyEQvF2=	MmK2V2FPT0WU
A498	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjhTWM2OD1yLkC3Nlg1KM7:TR?=	NXTOSnpxW0GQR1XS
TE-11	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn31TWM2OD1yLkC3PFU5KM7:TR?=	MYDTRW5ITVJ?
BB65-RCC	M1OwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLhTWM2OD1yLkC4NlI4KM7:TR?=	MUnTRW5ITVJ?
C2BBe1	M3PNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWP1[XhbUUN3ME2wMlA5OzB6IN88US=>	M4LpVHNCVkeHUh?=
NCI-H747	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTBwMEizOlIh\|ryP	M1HnU3NCVkeHUh?=
IST-MES1	M33KOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPJfZVKSzVyPUCuNFg2PTJizszN	NELscWJUSU6JRWK=
KALS-1	Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVW1fJo1UUN3ME2wMlA6PDlizszN	M4L6ZnNCVkeHUh?=
GCIY	NWfse41oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXjTWM2OD1yLkC5OlU3KM7:TR?=	NITqfphUSU6JRWK=
RL95-2	NF[yeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1n6[GlEPTB;MD6xNFM5KM7:TR?=	M2i5bHNCVkeHUh?=
TE-1	NFz3bYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfNNJhKSzVyPUCuNVA2PCEQvF2=	Mmq5V2FPT0WU
NCI-H1355	NIDXVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTBwMUGwNlgh\|ryP	NXnEXYc5W0GQR1XS
SW962	Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfP[2poUUN3ME2wMlEyOjl{IN88US=>	M4j6TnNCVkeHUh?=
KLE	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF24WVlKSzVyPUCuNVE{OTdizszN	MkfGV2FPT0WU
MC116	NGCydoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnqzTWM2OD1yLkGxOFEh\|ryP	NEf5dZVUSU6JRWK=
NMC-G1	NF3Dd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXFTWM2OD1yLkGxOlA3KM7:TR?=	NUnSS\|V4W0GQR1XS
KU812	MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDtTWM2OD1yLkGxPFg{KM7:TR?=	NF7jbZpUSU6JRWK=
COLO-829	NV6zclY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTBwMUKyNVMh\|ryP	NXfLPFlmW0GQR1XS
NTERA-S-cl-D1	NHH5eXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7hTWM2OD1yLkGyNlg{KM7:TR?=	NFr3[2NUSU6JRWK=
IST-MEL1	NF;qbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTBwMUO0OUDPxE1?	M13YV3NCVkeHUh?=
MLMA	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknmTWM2OD1yLkG0NFMzKM7:TR?=	MV;TRW5ITVJ?
LS-123	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTBwMUSwOlQh\|ryP	NIPRW4tUSU6JRWK=
LB2518-MEL	NV\6NYhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXVTWM2OD1yLkG0NVYzKM7:TR?=	NGHuO5VUSU6JRWK=
NB69	MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTBwMUS0N\|Yh\|ryP	NUO3RWpPW0GQR1XS
8-MG-BA	NEmxb\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnKTWM2OD1yLkG1OFU5KM7:TR?=	M4S0dHNCVkeHUh?=
K5	M33WOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTBwMU[0PFkh\|ryP	NHXhTHNUSU6JRWK=
KINGS-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTYdWVvUUN3ME2wMlE3PjZ4IN88US=>	MV3TRW5ITVJ?
SF268	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLKe2p2UUN3ME2wMlE4PDB2IN88US=>	NXK0cGtzW0GQR1XS
PF-382	MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\TZYRKUUN3ME2wMlE4Pjd6IN88US=>	NEjWcXNUSU6JRWK=
SH-4	M2j3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3IO3lKSzVyPUCuNVg1OTNizszN	NGPV[5ZUSU6JRWK=
NALM-6	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\KOXpiUUN3ME2wMlE6Ojl3IN88US=>	MnvkV2FPT0WU
CP66-MEL	NYOzS3hqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTE[VBKSzVyPUCuNVk2OzFizszN	M{fmcXNCVkeHUh?=
697	M4n1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHETWM2OD1yLkG5PVg4KM7:TR?=	NFuyXXFUSU6JRWK=
CP67-MEL	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIX4b2JKSzVyPUCuNlA1QDhizszN	NFnVRlhUSU6JRWK=
DSH1	NFfa[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHz4OY9KSzVyPUCuNlQxODFizszN	NWnJPXZ6W0GQR1XS
HCE-4	NV\DS4dZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPUUok5UUN3ME2wMlI3PDN7IN88US=>	Mly3V2FPT0WU
MZ2-MEL	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HVSmlEPTB;MD6yPFU{PyEQvF2=	M4\zVnNCVkeHUh?=
BL-41	NIWzUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTZTWM2OD1yLkK5NVI{KM7:TR?=	NF\ZOmVUSU6JRWK=
HUTU-80	NEnVV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTBwM{G0NkDPxE1?	NUnVPVRTW0GQR1XS
LOXIMVI	NFPke3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fsbmlEPTB;MD6zNVUxOyEQvF2=	Mmm3V2FPT0WU
no-10	MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHf1OpBKSzVyPUCuN\|E6OzFizszN	MYfTRW5ITVJ?
KARPAS-422	M2\0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zoPGlEPTB;MD6zN\|k6PyEQvF2=	MkL4V2FPT0WU
SW684	NXr3SGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\FTVJKSzVyPUCuN\|Q6QCEQvF2=	NYPU[4l1W0GQR1XS
SF126	MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3X1O2lEPTB;MD6zOVQyKM7:TR?=	NELzPZdUSU6JRWK=
D-263MG	NVS1fotyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPXeXc5UUN3ME2wMlM3OjJ2IN88US=>	MnrBV2FPT0WU
OVCAR-4	NEPNfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3[5NGlEPTB;MD6zO\|Q{OyEQvF2=	NEHpS2VUSU6JRWK=
BB49-HNC	M2PEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\NRWlEPTB;MD6zPFU6QSEQvF2=	M{fNOnNCVkeHUh?=
ONS-76	NUDNVGZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTBwNEK5OVEh\|ryP	MlzLV2FPT0WU
MZ7-mel	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1T5emlEPTB;MD60O\|kyOSEQvF2=	NW[1c2IxW0GQR1XS
RCC10RGB	NHLRbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDHbIJFUUN3ME2wMlQ6OTFizszN	M3T6XHNCVkeHUh?=
BOKU	NEnSUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3n4OmlEPTB;MD60PVE{OyEQvF2=	MkjkV2FPT0WU
no-11	NIjjVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvYTWM2OD1yLkWwNlI5KM7:TR?=	MXHTRW5ITVJ?
IST-SL2	MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\NRmlEPTB;MD61NFMxOiEQvF2=	M365bnNCVkeHUh?=
RKO	Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LUSGlEPTB;MD61Nlk3PiEQvF2=	MonwV2FPT0WU
HT-144	NF3rXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrsPXpKSzVyPUCuOVM3ODlizszN	Mli1V2FPT0WU
NCI-H446	Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXMTWM2OD1yLk[yO\|Yh\|ryP	MXLTRW5ITVJ?
QIMR-WIL	NU\GOJhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vzUGlEPTB;MD63NFYzQSEQvF2=	NUDEOY9XW0GQR1XS
MHH-PREB-1	M2XJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYmydI5XUUN3ME2wMlc1PDZ7IN88US=>	M4fm[XNCVkeHUh?=
EW-16	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwN{[xO\|gh\|ryP	MU\TRW5ITVJ?
EW-24	Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LMVmlEPTB;MD63PFE3PSEQvF2=	M4fae3NCVkeHUh?=
LB373-MEL-D	NW\jVHMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTBwOEK1NFgh\|ryP	NVq1R45rW0GQR1XS
TE-9	NXS1VI1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLrRZJKSzVyPUCuPFc2OzJizszN	NXLzVpM5W0GQR1XS
A3-KAW	NFTMS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLQdnBQUUN3ME2wMlk5PDV{IN88US=>	M3fwZ3NCVkeHUh?=
A101D	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnDXFI2UUN3ME2xMlA{ODR\|IN88US=>	MVjTRW5ITVJ?
OCUB-M	M4HnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVz0OIV[UUN3ME2xMlA1PDF{IN88US=>	NWqzemxiW0GQR1XS
ES4	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\zXGlEPTB;MT6wOVE1PSEQvF2=	Mn3WV2FPT0WU
TE-6	NYmzNWxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1L5SWlEPTB;MT6yNVIzPiEQvF2=	NFrtWHJUSU6JRWK=
D-502MG	NWPwboFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\BTWM2OD1zLkKzN\|c3KM7:TR?=	NIm3NGxUSU6JRWK=
KNS-42	NWj5PVNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTFwMkS0NVIh\|ryP	MV;TRW5ITVJ?
SNU-C2B	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrwXXBKSzVyPUGuN\|A2QDlizszN	NEj3OIZUSU6JRWK=
NCI-H1838	M4m5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTFwM{C3N\|Mh\|ryP	Ml7kV2FPT0WU
NKM-1	M4r2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3i1ZWlEPTB;MT6zNFg2QSEQvF2=	M3HRRXNCVkeHUh?=
GI-1	NHvOd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHJWG9KSzVyPUGuN\|YzOiEQvF2=	NHzvdFFUSU6JRWK=
NB5	NWDVbpBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXuPZBKSzVyPUGuN\|k5OjdizszN	MoP4V2FPT0WU
CAS-1	NY\hRWc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jkRmlEPTB;MT60NFk6OiEQvF2=	MUDTRW5ITVJ?
HCE-T	M1LsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\GVWlEPTB;MT61OlcyPCEQvF2=	NXLHbZNjW0GQR1XS
SBC-1	NFLrZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DBcmlEPTB;MT61O\|k5PCEQvF2=	NFLOeJRUSU6JRWK=
JiyoyeP-2003	Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPpPY9KSzVyPUGuO\|M1PjZizszN	M3vUV3NCVkeHUh?=
TE-5	NIm3d\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4myRWlEPTB;MT63PVE{QSEQvF2=	M3LWOXNCVkeHUh?=
CAN	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnFWXl7UUN3ME2xMlgzOjV{IN88US=>	M17jUnNCVkeHUh?=
SK-UT-1	M{\3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHSTWM2OD1{LkG2Olk{KM7:TR?=	Mof0V2FPT0WU
JVM-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfte4xKSzVyPUKuN\|YzQDRizszN	M4DhSXNCVkeHUh?=
LB771-HNC	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXZboF5UUN3ME2yMlU4PTVzIN88US=>	M{nhR3NCVkeHUh?=
NCCIT	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHX1RYJKSzVyPUKuPFY3OTZizszN	NETL[GtUSU6JRWK=
NCI-H2126	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV[yTllNUUN3ME2yMlg4PTV{IN88US=>	M{DMWnNCVkeHUh?=
Calu-6	NWjJeoIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rz[GlEPTB;Mz6wOVc1OSEQvF2=	M3y3NHNCVkeHUh?=
SK-LMS-1	NHnSfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnf5TWM2OD1\|LkGxPFg3KM7:TR?=	Ml35V2FPT0WU
ARH-77	M2juPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjSPFY3UUN3ME2zMlQ3QTF3IN88US=>	M3HyTXNCVkeHUh?=
NB17	M{m0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4W4OmlEPTB;Mz62N\|g1PyEQvF2=	M2jmOXNCVkeHUh?=
A253	MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\kR4RKSzVyPUOuO\|MzPDZizszN	M3W4enNCVkeHUh?=
OPM-2	NU[wOI5wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTRwMke2PFUh\|ryP	NXHhTlJ1W0GQR1XS
MV-4-11	NUTGSpc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTRwM{[0OVQh\|ryP	NWK1PIl[W0GQR1XS
SR	M{n3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnv2TWM2OD12LkS5PVU1KM7:TR?=	MUTTRW5ITVJ?
KG-1	MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDOTWM2OD12Lk[wPFQ2KM7:TR?=	NV;ZW4cyW0GQR1XS
OCI-AML2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXFU4dKSzVyPUWuPFYyPTRizszN	NGnwblhUSU6JRWK=
D-247MG	NGjWOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\IPIU3UUN3ME22MlEzPTF7IN88US=>	MUDTRW5ITVJ?
DJM-1	Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIT4SG1KSzVyPU[uOFg2PThizszN	Mkj3V2FPT0WU
RPMI-6666	NVGwfIp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXu3c49{UUN3ME23MlI4ODZ5IN88US=>	NXfWR4RnW0GQR1XS
KARPAS-45	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTdwNUG2O\|Eh\|ryP	M2DsXHNCVkeHUh?=
LP-1	NH\NdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnM[5FIUUN3ME23MlU1Pzh{IN88US=>	MV;TRW5ITVJ?
RS4-11	NEnLdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3n4bmlEPTB;Nz62OVc5PyEQvF2=	NW\GbGhuW0GQR1XS
DU-4475	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PzRWlEPTB;OD6yNVY2OiEQvF2=	NYX4TZdRW0GQR1XS
MONO-MAC-6	NGC2ZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\UTWM2OD16LkK3NFY3KM7:TR?=	MXrTRW5ITVJ?
NCI-SNU-16	NH\wSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\ROJRxUUN3ME24MlU3OTJ6IN88US=>	M1vsOXNCVkeHUh?=
SJSA-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHIRYtKSzVyPUiuO\|I5ODVizszN	NEHjeVZUSU6JRWK=
MMAC-SF	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRThwN{mzNFch\|ryP	NWr2dpJwW0GQR1XS
SK-NEP-1	NGHZcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXoSoNKSzVyPUiuPFkyPTVizszN	NYHxPFhzW0GQR1XS
J-RT3-T3-5	NFTycmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDnTWM2OD16Lkm2OVI6KM7:TR?=	MmLuV2FPT0WU
SKM-1	NXi2[mViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjyU2lVUUN3ME25MlAyPzN2IN88US=>	MX\TRW5ITVJ?
LB2241-RCC	NYDwcVU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jBfWlEPTB;OT6wNlAyOiEQvF2=	NW\HdWZiW0GQR1XS
SIG-M5	NHTnR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHq4[lhKSzVyPUmuNFI1QTNizszN	NWP6dHpFW0GQR1XS
EVSA-T	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlWyTWM2OD17LkK3O\|k{KM7:TR?=	MUnTRW5ITVJ?
GT3TKB	NX7CVlJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGOzcXpKSzVyPUmuN\|U2PDZizszN	NUT3enVEW0GQR1XS
NB6	NETyfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTlwOUKyOVkh\|ryP	NX:zSmRwW0GQR1XS
EHEB	MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzITWM2OD1zMD6wOlU3KM7:TR?=	M4TxZnNCVkeHUh?=
HEL	M3jQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPxTWM2OD1zMD60O\|c3KM7:TR?=	M3\pUHNCVkeHUh?=
ALL-PO	MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTFyLke5N\|gh\|ryP	MojxV2FPT0WU
TGW	MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoD6TWM2OD1zMT6yPFI5KM7:TR?=	MnrHV2FPT0WU
BC-3	M4TEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XMZWlEPTB;MUKuNVE{QCEQvF2=	NVHpVGY6W0GQR1XS
IA-LM	MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV:5OodlUUN3ME2xNk41PDR3IN88US=>	NUnGUlZsW0GQR1XS
UACC-257	M2nFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTF{LkmxPVgh\|ryP	M2PCT3NCVkeHUh?=
KP-N-YS	NXjDNlU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LRb2lEPTB;MUKuPVI5OyEQvF2=	NYjvcoNmW0GQR1XS
Raji	NVjGbHl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTF\|Lke0PVch\|ryP	M1;xWHNCVkeHUh?=
SF539	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHr1d4tKSzVyPUGzMlg2PTdizszN	NXLDSohXW0GQR1XS
DMS-153	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTF2LkCwNlgh\|ryP	Mmf2V2FPT0WU
L-540	NYXrSppjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTF3LkC2O\|Ih\|ryP	MWjTRW5ITVJ?
MN-60	NFvQZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrmTWM2OD1zNT6xPVc6KM7:TR?=	M{PUdXNCVkeHUh?=
RPMI-8866	NUfySItjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfhcIRlUUN3ME2xO{41PDV2IN88US=>	Mkn1V2FPT0WU
NCI-H510A	NYL6NolWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzR[lZKSzVyPUG5MlM6PzNizszN	NFPGfZBUSU6JRWK=
NB13	M4XodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTF7LkS4O\|ch\|ryP	Mn7PV2FPT0WU
HAL-01	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml2wTWM2OD1zOT63OVQ{KM7:TR?=	NV21dW4{W0GQR1XS
NCI-H720	NEn3Zo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnm0TWM2OD1{MD6yO\|M{KM7:TR?=	NU\yPXlUW0GQR1XS
REH	Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTJyLk[zOVch\|ryP	NWPPS49TW0GQR1XS
KNS-81-FD	Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moj5TWM2OD1{Mz6xOFYh\|ryP	MlTxV2FPT0WU
HC-1	MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzGTWw{UUN3ME2yOE42PTVzIN88US=>	MVLTRW5ITVJ?
NCI-H2141	NVPSXW52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHmS\|lKSzVyPUK0Mlc4PTRizszN	NV7Vd2JJW0GQR1XS
MOLT-4	MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\3TWM2OD1{Nj62O\|U{KM7:TR?=	MnvZV2FPT0WU
OMC-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjiXZFNUUN3ME2yO{4yPDJ{IN88US=>	M4[1UXNCVkeHUh?=
LC-1F	NVfSXmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfxfHhqUUN3ME2yO{4{OjR3IN88US=>	NXPzUpYyW0GQR1XS
NCI-H1304	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDQTWM2OD1{OD6xOlI5KM7:TR?=	NVHMflBPW0GQR1XS
BC-1	Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPYTWM2OD1{OD62OVEh\|ryP	NV\uWpJpW0GQR1XS
NCI-H64	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnryTWM2OD1{OT62NlU{KM7:TR?=	MVjTRW5ITVJ?
MOLT-16	MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLXTWM2OD1{OT62NlkzKM7:TR?=	NY\yOlVpW0GQR1XS
U-87-MG	NW\pe5RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTNyLke2OkDPxE1?	MoDZV2FPT0WU
GAK	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV6xZ3VIUUN3ME2zNU4zPjh4IN88US=>	Moq4V2FPT0WU
ES8	M2na[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjnPWhKUUN3ME2zNk4yOjV{IN88US=>	MmDVV2FPT0WU
HCC1599	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTN{LkOzNlUh\|ryP	M2PKVHNCVkeHUh?=
EB-3	NVf6cm9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13qUGlEPTB;M{SuN\|EyPyEQvF2=	NF;iU49USU6JRWK=
HCC1187	NFPN[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPpVVd5UUN3ME2zOU45ODV{IN88US=>	M3XZfHNCVkeHUh?=
SK-PN-DW	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfXUlAzUUN3ME2zOk4yQTR\|IN88US=>	NELHUHFUSU6JRWK=
JVM-3	NY\rV45sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTOSmNYUUN3ME2zO{4zOzN6IN88US=>	NWPVdXFOW0GQR1XS
HCC2157	M2TzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTQTWM2OD1\|Nz65PVQ3KM7:TR?=	NHHNNXhUSU6JRWK=
A4-Fuk	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfiPG5DUUN3ME2zPE4yODB7IN88US=>	MmjpV2FPT0WU
COR-L279	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoD6TWM2OD12MD6yPFUyKM7:TR?=	NF;KWmRUSU6JRWK=
DEL	Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXf6enVJUUN3ME20NU46ODh4IN88US=>	M{nhWnNCVkeHUh?=
NCI-H1395	NFnGNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fmfWlEPTB;NEKuNFE3OyEQvF2=	MmfRV2FPT0WU
MHH-NB-11	MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPXb2dlUUN3ME20N{4xQDF6IN88US=>	NFWxSZVUSU6JRWK=
NCI-H2107	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HGemlEPTB;NEOuOFg1PiEQvF2=	NEDG[pdUSU6JRWK=
NEC8	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvzWlhKSzVyPUS0MlM{PiEQvF2=	NGD2SZZUSU6JRWK=
COLO-684	NWLRV\|J1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzUW291UUN3ME20Ok4zOjV6IN88US=>	MXfTRW5ITVJ?
LS-411N	MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1i3UGlEPTB;NEiuOFc1QCEQvF2=	M133W3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	- Collapse Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Formulation: DMSO Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- Collapse

Solubility (25°C)

In vitro	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib SDF

Molecular Weight	488.01
Formula	C₂₂H₂₆ClN₇O₂S
CAS No.	302962-49-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	BMS-354825

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Not yet recruiting	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	December 2019	Phase 1\|Phase 2
NCT04115059	Not yet recruiting	Drug: Dasatinib	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 2019	Phase 1
NCT03318770	Not yet recruiting	Drug: Dasatinib and blinatumomab	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Drug: Dasatinib	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2
NCT03193281	Recruiting	Drug: Dasatinib\|Drug: Imatinib	Chronic Myeloid Leukemia	University of Auckland New Zealand\|Leukaemia & Blood Cancer New Zealand	July 17 2017	Phase 2
NCT03041701	Recruiting	Drug: Dasatinib\|Drug: Ganitumab	Rhabdomyosarcoma\|Rhabdomyosarcoma- Alveolar\|Rhabdomyosarcoma-Embryonal	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	July 7 2017	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
Question 2:
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
Answer:
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Pan Src Inhibitor

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products

Dasatinib Monohydrate ^New

Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
KX2-391（Tirbanibulin）

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib

Cited by 220 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dasatinib SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib

Cited by 220 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dasatinib SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)